VivoSeq
Oncology

Advanced Ovarian Cancer

6

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Advanced Ovarian Cancer is an early-stage landscape with 6 programs across 3 companies. The most active players are AstraZeneca, Avyxa, Aya Ahmed Nasser. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

4 programs

Phase 3A

Avyxa

1 program

Phase 3A

Aya Ahmed Nasser

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 36

Bevacizumab

Bio-Thera Solutions

Durvalumab

AstraZeneca

Olaparib

AstraZeneca

Placebo Olaparib

AstraZeneca

Durvalumab Placebo

AstraZeneca

Approved
No programs

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody250%

Modality classified for 67% of 6 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT03737643·1,407 enrolled
Integrative Prognostic Value of Inflammatory Markers and KELIM Score in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy.
Active, not recruiting·—·N/A·NCT07678008·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)